Piro Lito, M.D., Ph.D.

Mutations in the KRAS gene are one of the most frequent genetic alterations found in lung cancer, a disease that is associated with the highest cancer-related morality rate in the US. Despite their prevalence, we still do not have an effective therapeutic intervention to target lung cancers harboring KRAS mutations. In this application we will investigate novel approaches to inhibit the function of this protein in patient-derived (or ‘avatar’) models of lung cancer and then translate the most promising findings to early phase clinical trials.

Location: Memorial Sloan-Kettering Cancer Center - NY
Proposal: Establishing a KRAS mutant-directed therapy against lung cancer
Mailing List Mailing List
Close Mailing List